Clinical Trial Update: NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines [Phase 3]

View source ↗

Summary

Phase 3 study comparing NT 201 (Xeomin/Bocouture) with botulinum toxin type A for treating glabellar frown lines; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines

Drugs mentioned

• Clostridium botulinum toxin type A (onabotulinumtoxinA) (onabotulinumtoxinA)
• Xeomin/Bocouture (incobotulinumtoxinA)

Snippet

Sponsor: Merz Pharmaceuticals GmbH | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED | Results posted: 2012-02-10